EBR Systems, Inc.
7
2
4
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
The WiSE®-UP Registry (The WiSE System Utilization & Performance Registry)
Role: lead
A Feasibility Study Implant of the WiSE® CRT System With an Intracardiac Pacemaker to Achieve Totally Leadless CRT
Role: lead
Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients
Role: lead
WiCS-LV Post Market Surveillance Registry
Role: lead
Implant of the WiSE CRT System With an Intracardiac Pacemaker
Role: collaborator
Safety and Performance of Electrodes Implanted in the Left Ventricle
Role: lead
Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy
Role: lead
All 7 trials loaded